A Phase 1 interventional study of Daclatasvir and Darunavir in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-30.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.
Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 42nd largest by enrollment, is one of 13 that started in 2014, is one of 10 in phase 1, and was the 36th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 25 · Phase 4 5
First in 2009; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 100 across the 59 interventional studies. Of the 53 that completed or were terminated, 25 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 59 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
78 studies in Hepatitis C by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 70 finished, 25 (36%) have results posted.
Among the 78 studies in Hepatitis C by Bristol-Myers Squibb, this one is the 44th largest by enrollment of the 67 interventional ones that give a count, is one of 20 that started in 2014, is one of 20 in phase 1, and was the 60th registered.
Bristol-Myers Squibb’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing daclatasvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 78 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: Daclatasvir oral tablet on specific days Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days
Drug: Daclatasvir · Drug: Darunavir · Drug: Ritonavir
Treatment C: Daclatasvir oral tablet on specific days Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days
Drug: Daclatasvir · Drug: Ritonavir · Drug: Lopinavir/Ritonavir
Also known as: BMS-790052
Also known as: Prezista
Also known as: Norvir
Maximum Observed Plasma Concentration (Cmax) for Daclatasvir
Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir
AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir
Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir
C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir
Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir
AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.
Time frame: From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)
Number of Participants With Abnormalities in Vital Sign Measurements
Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value \>90 and change from baseline \> 0 or value \< 55 and change from baseline \<-10. Systolic blood pressure: Value \>140 and change from baseline \>20 or value \<90 and change from baseline \<-20. Heart rate: Value \>100 and change from baseline \>30 or value \<55 and change from baseline \<-15. Respiration: Value \>16 or change from baseline \>10. Temperature: Value \>38.3°C or change from baseline \>1.6°C.
Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)
Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.
Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)
Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results
Criteria for marked abnormalities in test results: Platelet count \>1.5\*upper limits of normal (ULN) value, \>1.5\*ULN if pretreatment (PreRx) value is missing, \<0.85\*lower limit of normal (LLN) if PreRx ≥LLN, \<0.85\*LLN if PreRx is missing, \<0.85\*PreRx if PreRx \<LLN. Leukocytes \>1.2\*ULN if LLN ≤PreRx ≤ULN, \>1.2\*ULN if PreRx is missing, \>1.5\*PreRx if PreRx \>ULN, \>ULN if PreRx \<LLN, \<0.85\*PreRx if PreRx \<LLN, \<0.9\*LLN if LLN ≤PreRx ≤ULN, \<0.9\*LLN if PreRx is missing and \<LLN if PreRx \>ULN. Lymphocytes \>7.5\*10\^3 c/uL and \<0.75\*10\^3 c/uL. Neutrophils \<0.85\*PreRx if PreRx \<1.5\*ULN, \<1.5\*ULN if PreRx ≥1.5\*ULN and \<1.5\*ULN if PreRx is missing.
Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)
Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results
Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) \<1, ≥2 if PreRx is missing or ≥2\*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase \>1.25\*upper limit of normal (ULN) if PreRx ≤ULN, \>1.25\*ULN if PreRx is missing and \>1.5\*PreRx if PreRx \>ULN.
Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)
Participants were enrolled at 1 site in the United States of America.
| Milestone | Daclatasvir + Darunavir/Ritonavir | Daclatasvir + Lopinavir/Ritonavir |
|---|---|---|
| Started | 14 | 14 |
| Phase 1 (day 1- 4) | 14 | 14 |
| Phase 2 (day 5-14) | 11 | 12 |
| Completed | 11 | 12 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.
| ng/mL | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Daclatasvir | 1335 ± 38 | 493 ± 36 | 1412 ± 28 | 476 ± 21 |
AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.
| ng*h/mL | Daclatasvir (60 mg) Days 1-4 | Daclatasvir (30 mg) + Darunavir/Ritonavir Days 5-14 | Daclatasvir (60 mg) Days 5-14 | Daclatasvir (30 mg) + Lopinavir/Ritonavir Days 5-14 |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir | 12677 ± 41 | 8295 ± 39 | 13799 ± 26 | 7855 ± 23 |
Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.
| hours | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir | 2.00 (1.00 to 6.00) | 3.00 (1.00 to 6.00) | 2.00 (1.00 to 6.00) | 2.00 (1.00 to 11.93) |
C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
| ng/mL | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir | 225 ± 54 | 250 ± 45 | 225 ± 36 | 280 ± 29 |
Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
| ng/mL/mg | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Cmax/D | 22.2 ± 38 | 16.4 ± 36 | 23.5 ± 28 | 15.9 ± 21 |
| C24/D | 3.75 ± 54 | 8.34 ± 45 | 3.76 ± 36 | 9.33 ± 29 |
AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.
| (ng*h/mL)/mg | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir | 211 ± 41 | 276 ± 39 | 230 ± 26 | 262 ± 23 |
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.
| participants | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| SAE | 0 | 0 | 0 | 0 |
| Discontinued due to AEs | 0 | 3 | 0 | 1 |
| Death | 0 | 0 | 0 | 0 |
Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value \>90 and change from baseline \> 0 or value \< 55 and change from baseline \<-10. Systolic blood pressure: Value \>140 and change from baseline \>20 or value \<90 and change from baseline \<-20. Heart rate: Value \>100 and change from baseline \>30 or value \<55 and change from baseline \<-15. Respiration: Value \>16 or change from baseline \>10. Temperature: Value \>38.3°C or change from baseline \>1.6°C.
| participants | Group 1: Daclatasvir + Darunavir/Ritonavir | Group 2: Daclatasvir + Lopinavir/Ritonavir |
|---|---|---|
| Number of Participants With Abnormalities in Vital Sign Measurements | 3 | 2 |
Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.
| participants | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| PR >210 | 2 | 4 | 0 | 1 |
| QRS >120 | 0 | 0 | 0 | 0 |
| QT >500 | 0 | 0 | 0 | 0 |
| QTcF >450 | 0 | 1 | 0 | 0 |
Criteria for marked abnormalities in test results: Platelet count \>1.5\*upper limits of normal (ULN) value, \>1.5\*ULN if pretreatment (PreRx) value is missing, \<0.85\*lower limit of normal (LLN) if PreRx ≥LLN, \<0.85\*LLN if PreRx is missing, \<0.85\*PreRx if PreRx \<LLN. Leukocytes \>1.2\*ULN if LLN ≤PreRx ≤ULN, \>1.2\*ULN if PreRx is missing, \>1.5\*PreRx if PreRx \>ULN, \>ULN if PreRx \<LLN, \<0.85\*PreRx if PreRx \<LLN, \<0.9\*LLN if LLN ≤PreRx ≤ULN, \<0.9\*LLN if PreRx is missing and \<LLN if PreRx \>ULN. Lymphocytes \>7.5\*10\^3 c/uL and \<0.75\*10\^3 c/uL. Neutrophils \<0.85\*PreRx if PreRx \<1.5\*ULN, \<1.5\*ULN if PreRx ≥1.5\*ULN and \<1.5\*ULN if PreRx is missing.
| participants | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Platelet Count | 1 | 0 | 0 | 0 |
| Leukocytes | 0 | 1 | 1 | 1 |
| Neutrophils (absolute) | 0 | 2 | 1 | 0 |
| Lymphocytes (absolute) | 0 | 1 | 0 | 0 |
Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) \<1, ≥2 if PreRx is missing or ≥2\*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase \>1.25\*upper limit of normal (ULN) if PreRx ≤ULN, \>1.25\*ULN if PreRx is missing and \>1.5\*PreRx if PreRx \>ULN.
| participants | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|
| Blood, urine | 2 | 1 | 1 | 0 |
| RBC, urine | 1 | 1 | 0 | 0 |
| WBC, urine | 1 | 3 | 0 | 0 |
| Lactate dehydrogenase | 2 | 2 | 1 | 1 |
Collected over From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Total | — | 0/14 (0%) | 6/14 (42.9%) |
| Group 1: Daclatasvir (60 mg) | — | 0/14 (0%) | 1/14 (7.1%) |
| Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | — | 0/14 (0%) | 6/14 (42.9%) |
| Group 2: Total | — | 0/14 (0%) | 8/14 (57.1%) |
| Group 2: Daclatasvir (60 mg) | — | 0/14 (0%) | 3/14 (21.4%) |
| Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir | — | 0/14 (0%) | 8/14 (57.1%) |
| Event | Group 1: Total | Group 1: Daclatasvir (60 mg) | Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir | Group 2: Total | Group 2: Daclatasvir (60 mg) | Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/14 | 0/14 | 2/14 | 5/14 | 0/14 | 5/14 |
| NauseaGastrointestinal disorders | 0/14 | 0/14 | 0/14 | 4/14 | 2/14 | 2/14 |
| HeadacheNervous system disorders | 1/14 | 0/14 | 1/14 | 3/14 | 2/14 | 1/14 |
| Drug eruptionSkin and subcutaneous tissue disorders | 2/14 | 0/14 | 2/14 | 1/14 | 0/14 | 1/14 |
| Decreased appetiteMetabolism and nutrition disorders | 0/14 | 0/14 | 0/14 | 2/14 | 1/14 | 1/14 |
| Electrocardiogram PR prolongationInvestigations | 1/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 |
| Chest discomfortGeneral disorders | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 1/14 |
| Soft tissue injuryInjury, poisoning and procedural complications | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 1/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/14 | 1/14 | 1/14 | 0/14 |
| PresyncopeNervous system disorders | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 1/14 |
| Age, Customized(participants) | Daclatasvir + Darunavir/Ritonavir | Daclatasvir + Lopinavir/Ritonavir | Total |
|---|---|---|---|
| Between 18 and 65 years | 14 | 14 | 28 |
| Sex: Female, Male(Participants) | Daclatasvir + Darunavir/Ritonavir | Daclatasvir + Lopinavir/Ritonavir | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 9 | 10 | 19 |
The record gives a start of Jun 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daclatasvir · Darunavir · Ritonavir